Know Cancer

forgot password

Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA)

Phase 4
18 Years
Not Enrolling
Actinic Keratosis

Thank you

Trial Information

Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA)

Inclusion Criteria:

- Immunocompetent patient.

- A study treatment area must be identifiable: Minimum of 5 and maximum of 10 typical
visible AKs in one contiguous area of up to 50 cm2 on the face or scalp. The eyelids,
the inside of the nostrils or ears, or the lip area inside the vermilion border must
not be part of this area.

- A positive histological finding for AK grade I or II (see Section This will
be determined from the most suspicious lesion in the STA and there from the most
pathological area biopsied during screening visit. This analysis will be done by the
central histopathological laboratory.

- Willingness to comply with the obligations of the study.

Exclusion Criteria:

Safety concerns:

- History of allergic reaction to imiquimod, diclofenac, acetyl salicylic acid, other
non steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant

- Pregnancy, breast-feeding or planned pregnancy during the study. Women of child
bearing potential not using a highly effective method of birth control defined as
those which result in a low failure rate (i.e. <1% per year) when used consistently
and correctly such as implants, injectables, combined oral contraceptives, hormonal
IUDs, tubal ligation or vasectomised partner.

Lack of suitability for the study:

- Presence of AK lesions in the STA with clinically marked hyperkeratosis or
hypertrophy as seen in cutaneous horns.

- Any topical AK treatment including imiquimod or diclofenac, or any systemic AK
treatment such as systemic retinoids, or any surgical AK treatment at the STA within
the last 2 months prior to randomisation.

- Persisting AK lesion at screening visit following topical treatment with imiquimod or
diclofenac in the STA.

- Topical treatment with imiquimod or diclofenac anywhere else on the body within the
last 2 months prior to randomisation.

- Presence of any histologically confirmed skin tumour in the STA: in situ SCC
including Bowen's disease, invasive SCC, basal cell carcinoma, or other malignant

- Any dermatological disease or condition that may exacerbate by treatment with
imiquimod or diclofenac (e.g. rosacea, psoriasis, atopic dermatitis).

- Any dermatological disease or condition in the STA that causes difficulty with
examination (e.g. eczema).

- Systemic immunomodulatory treatment such as interferon, azathioprine, cyclosporine,
retinoids, any oral or injectable corticosteroids, or inhaled or nasal
corticosteroids with dosages of >1200 µg/day beclomethasone or equivalent within 4
weeks before start of study treatment.

- History of any malignant tumour with high tumour burden or any systemic antitumour
treatment (incl. radiotherapy).

- History of any malignant skin tumour having metastasised or where metastasis could be

- History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal,
haematological, endocrine, metabolic, mental, neurological, or other disease within
the last two years.

- Mentally incapacitated patient.

- Present or history of drug or alcohol abuse within the last 3 years.

Administrative reasons:

- Exposure to an investigational product within the last 3 months.

- Lack of ability or willingness to give informed consent.

- Age below 18 years.

- Lack of willingness to have personal study related data collected, archived or
transmitted according to protocol.

- Anticipated non-availability for study visits/procedures.

- Vulnerable subjects (such as persons kept in detention).

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Recurrence with respect to the study treatment area until month 12

Outcome Description:

A patient is classified as recurrent when cleared at Visit Week 20 and having later on at least one clinically diagnosed AK lesion in the study treatment area

Outcome Time Frame:

week 20 until month 12

Safety Issue:


Principal Investigator

Harald Gollnick, MD, Prof.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Otto-von-Guericke-University of Magdeburg/Germany, Clinic for Dermatology and Venereology


Austria: Federal Office for Safety in Health Care

Study ID:




Start Date:

December 2008

Completion Date:

November 2012

Related Keywords:

  • Actinic Keratosis
  • actinic keratosis
  • invasive SCC
  • in situ SCC
  • histological classification
  • histological progression
  • clinical clearance
  • cryotherapy
  • Keratosis
  • Keratosis, Actinic